Editorial Commentary
Physiologically based pharmacokinetic (PBPK) modeling: It is here to stay!
Amin Rostami-Hodjegan,
Ikumi Tamai, K. Sandy Pang,
Corresponding Author
Amin Rostami-Hodjegan
University of Manchester & Simcyp Limited, United Kingdom
University of Manchester & Simcyp Limited, United Kingdom.
E-mail: [email protected]
Search for more papers by this authorK. Sandy Pang
Leslie Dan Faculty of Pharmacy, University of Toronto, Canada
Search for more papers by this authorAmin Rostami-Hodjegan,
Ikumi Tamai, K. Sandy Pang,
Corresponding Author
Amin Rostami-Hodjegan
University of Manchester & Simcyp Limited, United Kingdom
University of Manchester & Simcyp Limited, United Kingdom.
E-mail: [email protected]
Search for more papers by this authorK. Sandy Pang
Leslie Dan Faculty of Pharmacy, University of Toronto, Canada
Search for more papers by this author
References
- 1 Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011; 89: 259–267.
- 2 Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth 2011; 21: 291–301.
- 3 Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45–73.
- 4 Bouzom F, Ball K, Perdaems N, Walther B. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm Drug Dispos in this issue.
- 5 Chen Y, Jin JY, Mukadam S, Malhi V, Kenny JR. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm Drug Dispos in this issue.
- 6 Shaffer CL, Scialis RJ, Rong H, Obach RS. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events. Biopharm Drug Dispos in this issue.
- 7 Sinha VK, Snoeys J, Van Osselaer N, Van Peer A, Mackie C, Heald D. From preclinical to human – prediction of oral absorption and drug–drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in industrial setting: a workflow by using case example. Biopharm Drug Dispos in this issue.
- 8 Huang SM, Rowland M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther 2012; 91: 542–549.
- 9 Grillo JA, Zhao P, Bullock J, et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario with rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos in this issue.
